The city of Ann Arbor, Michigan, currently has 180 active clinical trials seeking participants for Cancer research studies.
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Recruiting
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Oropharynx Cancer, HPV-Related Carcinoma
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
Recruiting
The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Breast Cancer
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
Recruiting
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results. Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy. Retrospective collection of treatment related AEs and SAEs, dose delays, dose reductions, and treatment discontinuations will be completed.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Cancer
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
Recruiting
This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19. Cycle length will be 28 days. Patients will be monitored closely for toxicity and undergo imaging to evaluate efficacy once every 2 cycles.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Thyroid Cancer
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Recruiting
Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Prostate Cancer Metastatic, Neuroendocrine Tumors
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Recruiting
This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Recruiting
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy [SBRT]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/15/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Prostate Cancer
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Recruiting
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is impo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: University of Michigan Health System, Ann Arbor, Michigan
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Childhood Cancer Survivor Study
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
All
Ages:
All
Trial Updated:
12/11/2023
Locations: University of Michigan/Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Cancer
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
Recruiting
The study will include 50 patients newly diagnosed with low-risk thyroid cancer ranging from 18-80 years of age. After scheduling their surgeon visit, the investigators will enroll patients and measure their intended treatment choice, baseline awareness of the three treatment options, expected outcomes, self-efficacy, and activation. The participants will then be randomized 1:1 and deliver the CQUPLE intervention to the intervention group. The control group will receive usual care, which involve... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/11/2023
Locations: The University of Michigan Cancer Center, Ann Arbor, Michigan
Conditions: Thyroid Cancer
CLEAR Care Companion Application
Recruiting
Hospital readmissions are common after major cancer surgery, leading to poorer patient outcomes, increased mortality and additional costs. In this study, Clinical and Engineering Approaches to Readmission (CLEAR) Care Companion Application, investigators aim to utilize a smartphone application that tracks concerning postoperative symptoms and provides educational interventions to determine if this can minimize delays in communication between patients and medical providers, increase patient satis... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Bladder Cancer, Radical Cystectomy